Phase III
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
This morning, the Swiss pharma giant announced Ilaris plus standard of care did not demonstrate a significantly greater chance of survival for patients without the need for invasive mechanical ventilation, compared with placebo plus the standard of care.
There was a handful of positive clinical trial news reported today. Here’s a look.
The company announced positive topline results in its Phase III study of Xpovio (selinexor) in patients with advanced unresectable dedifferentiated liposarcoma, which sets up potential approval in this indication.
Three biopharma companies recently shuttered their clinical programs after either their compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
GW Pharmaceuticals hopes to bring its cannabis-based treatment nabiximols for multiple sclerosis spasticity to the United States.
“With limited oral therapeutic options available for psoriasis, there remains a significant need for safe and effective therapies,” said April Armstrong, associate dean and professor of dermatology at the University of Southern California.
The decision to halt critically ill patients was made in response to Regeneron’s independent safety board finding a potential safety signal and an unfavorable risk-benefit profile of the monoclonal antibody therapy in a subgroup of patients requiring high-flow oxygen or mechanical ventilation.
It was a particularly busy week for announcements about clinical trials, both related to COVID-19 and everything else. Here’s a look.
PRESS RELEASES